Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMartin Currie Global Portfolio Trust Regulatory News (MNP)

Share Price Information for Martin Currie Global Portfolio Trust (MNP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 369.00
Bid: 369.00
Ask: 370.00
Change: 4.00 (1.10%)
Spread: 1.00 (0.271%)
Open: 366.00
High: 370.00
Low: 366.00
Prev. Close: 365.00
MNP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

21 Apr 2021 14:06

RNS Number : 2020W
Martin Currie Global Portfolio Tst
21 April 2021
 

Martin Currie Global Portfolio (MNP)

21/04/2021

 

Results analysis from Kepler Trust Intelligence

· Today Martin Currie Global Portfolio (MNP) released its annual results for the period ending January 2021. Over the year, the trust delivered NAV total returns of 20.2%, with a share price total return of 20.5%. Outperforming the benchmark MSCI All World Country Index, which returned just 12.3%. (Source: Martin Currie)

· The trust has paid three interim dividends of 0.9 pence per share and intends to pay a fourth interim dividend of 1.5 pence per share. Total dividends are thus in line with the previous year, an impressive feat given the economic conditions.

· The board have continued to make progressive developments in its goal of growing the trust, including a new gearing facility and an improved fee structure.

Kepler View

While the pandemic has been a challenging environment for many global managers, MNP has been able the thrive over this period. By utilising a scenario forecasting and stress testing they have been able to avoid some of the companies worst effected by COVID-19.

This can be seen in MNP's performance, where it outperformed the MSCI ACWI Index by 7.9% over the 12 month period, despite its diversified yet highly concentrated portfolio not holding many of the mega cap tech names which were often the headline outperformers during the pandemic. Looking forward we see MNP's proposition being increasingly attractive thanks to the changes being made to the trusts gearing and cost structure.

We believe that MNP continues to simultaneously offer the enviable combination diversification benefits and strong performance, avoiding many of the companies which dominate global indices. Given the further potential for strong performance, thanks to the manager's use of sectoral analysis, the slight 1.2% premium MNP trades on is a small price to pay for a differentiated yet successful global equity stagey.

Overall 2020 has clearly demonstrated the effectiveness of MNP's process and with its current manager, Zehrid Osmani, continuing to successfully develop his tenure with the strategy, as well the board intended to grow the trust, MNP looks to remain an attractive option for a global equity allocation.

CLICK HERE TO READ THE FULL REPORT

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZGZDFMVGMZM
Date   Source Headline
3rd May 20244:48 pmRNSTransaction in Own Shares
3rd May 20248:47 amRNSNet Asset Value(s)
2nd May 20244:48 pmRNSTransaction in Own Shares
2nd May 20249:28 amRNSNet Asset Value(s)
1st May 20244:44 pmRNSTransaction in Own Shares
1st May 202411:07 amRNSQuarterly disclosure
1st May 202410:18 amRNSNet Asset Value(s)
1st May 20249:45 amRNSTotal Voting Rights
30th Apr 20244:51 pmRNSTransaction in Own Shares
30th Apr 20249:05 amRNSNet Asset Value(s)
29th Apr 20244:46 pmRNSTransaction in Own Shares
29th Apr 202410:11 amRNSNet Asset Value(s)
26th Apr 20244:45 pmRNSTransaction in Own Shares
26th Apr 20248:39 amRNSNet Asset Value(s)
25th Apr 20248:52 amRNSNet Asset Value(s)
24th Apr 20244:52 pmRNSTransaction in Own Shares
24th Apr 20249:12 amRNSChange of director details
24th Apr 20248:40 amRNSNet Asset Value(s)
23rd Apr 20245:21 pmRNSFinal Results
23rd Apr 20244:45 pmRNSTransaction in Own Shares
23rd Apr 20249:27 amRNSNet Asset Value(s)
22nd Apr 20244:54 pmRNSTransaction in Own Shares
22nd Apr 20248:47 amRNSNet Asset Value(s)
19th Apr 20244:52 pmRNSTransaction in Own Shares
19th Apr 20248:48 amRNSNet Asset Value(s)
18th Apr 20244:47 pmRNSTransaction in Own Shares
18th Apr 20248:55 amRNSNet Asset Value(s)
17th Apr 20244:46 pmRNSTransaction in Own Shares
17th Apr 20249:04 amRNSNet Asset Value(s)
16th Apr 20244:44 pmRNSTransaction in Own Shares
16th Apr 20248:37 amRNSNet Asset Value(s)
15th Apr 20244:50 pmRNSTransaction in Own Shares
15th Apr 20249:03 amRNSNet Asset Value(s)
12th Apr 20244:52 pmRNSTransaction in Own Shares
12th Apr 20249:06 amRNSNet Asset Value(s)
11th Apr 20244:51 pmRNSTransaction in Own Shares
11th Apr 20248:43 amRNSNet Asset Value(s)
10th Apr 20244:46 pmRNSTransaction in Own Shares
10th Apr 20248:52 amRNSNet Asset Value(s)
9th Apr 20244:51 pmRNSTransaction in Own Shares
9th Apr 20248:52 amRNSNet Asset Value(s)
8th Apr 20244:55 pmRNSTransaction in Own Shares
8th Apr 20248:48 amRNSNet Asset Value(s)
5th Apr 20248:47 amRNSNet Asset Value(s)
4th Apr 20244:50 pmRNSTransaction in Own Shares
4th Apr 20248:44 amRNSNet Asset Value(s)
3rd Apr 20244:48 pmRNSTransaction in Own Shares
3rd Apr 20249:16 amRNSNet Asset Value(s)
2nd Apr 20244:50 pmRNSTransaction in Own Shares
2nd Apr 20247:59 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.